3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
6
Phase 1
2
Phase NA
1
Phase 4
1
Phase 3
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Mycosis Fungoides
2
Carcinoma, Non-Small-Cell Lung
2
Sezary Syndrome
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Primary Cutaneous Anaplastic Large Cell
1
Lymphoma
1
Interventions
liposomal amphotericin B
2
hypericin
2
Vorinostat
2
Psychiatric Rehabilitation
2
Peripheral Blood Stem Cell Transplantation
2
Levofloxacin
2
Early Intervention, Educational
2
Darbepoetin alfa
2
Brentuximab Vedotin
2
zanolimumab
1
mogamulizumab
1
ferrous sulfate
1
ferric gluconate
1
Vancomycin
1
Valacyclovir
1
Therapeutics
1
Tazobactam
1
Sucrose
1
Ribavirin
1
Radiotherapy
1
Piperacillin, Tazobactam Drug Combination
1
Piperacillin
1
Phototherapy
1
Pharmacogenomic Testing
1
Palivizumab
1
Ondansetron
1
Moxifloxacin
1
Morphine
1
Methotrexate
1
Lenalidomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoma, T-Cell, Cutaneous
×
Bexarotene
×
Clear all
NCT01578499
2021-01-05
ALCANZA
Takeda
Phase 3
Completed
131 enrolled
24 charts